EGFR and metastatic neoplasm: Here, we report the results of a phase 2 study designed to evaluate the efficacy of mobocertinib 160 mg QD in Japanese patients with locally advanced or metastatic NSCLC whose tumors harbor EGFR exon 20 insertion mutations and who have not previously received systemic treatment for locally advanced or metastatic disease.